Prostate cancer, version 1.2014: Featured updates to the NCCN Guidelines Review uri icon

Overview

MeSH Major

  • Prostatic Neoplasms

abstract

  • The NCCN Guidelines for Prostate Cancer provide multidisciplinary recommendations on the clinical management of patients with prostate cancer. This report highlights notable recent updates. Radium-223 dichloride is a first-in-class radiopharmaceutical that recently received approval for the treatment of patients with symptomatic bone metastases and no known visceral disease. It received a category 1 recommendation as both a first-line and second-line option. The NCCN Prostate Cancer Panel also revised recommendations on the choice of intermittent or continuous androgen deprivation therapy based on recent phase III clinical data comparing the 2 strategies in the nonmetastatic and metastatic settings.

authors

publication date

  • December 2013

Research

keywords

  • Review

Identity

Language

  • eng

PubMed ID

  • 24335682

Additional Document Info

start page

  • 1471

end page

  • 9

volume

  • 11

number

  • 12